Chemotherapy for brain tumors with polymer drug delivery

Handbook of Clinical Neurology

Volumn 104, Issue , 2012, Pages 339-353

  Attenello, Frank ^a   Raza, Shaan M ^a   Dimeco, Francesco ^a   Olivi, Alessandro ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855554649     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52138-5.00022-0     Document Type: Chapter

References (131)

1. Abbott N.J., Romero I.A. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996, 2:106-113.
2. An B., Goldfarb R.H., Siman R., et al. Novel dipeptidyl proteasome inhibitors overcome bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998, 5:1062-1075.
3. Benoit J.P., Faisant N., Venier-Julienne M.C., et al. Development of microspheres for neurological disorders: from basics to clinical applications. J Control Release 2000, 65:285-296.
4. Bindschaedler C., Leong K., Mathiowitz E., et al. Polyanhydride microsphere formulation by solvent extraction. J Pharm Sci 1988, 77:696-698.
5. Boisdron-Celle M., Menei P., Benoit J.P. Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J Pharm Pharmacol 1995, 47:108-114.
6. Brady J.M., Cutright D.E., Miller R.A., et al. Resorption rate, route, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J Biomed Mater Res 1973, 7:155-166.
7. Brem H., Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975, 141:427-439.
8. Brem H., Langer R. Polymer-based drug delivery to the brain. Sci Med 1996, 52-61. July/August:.
9. Brem H., Kader A., Epstein J.I., et al. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel Cancer Ther 1989, 5:55-65.
10. Brem H., Mahaley M.S., Vick N.A., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991, 74:441-446.
11. Brem H., Tamargo R.J., Olivi A., et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994, 80:283-290.
12. Brem H., Ewend M.G., Piantadosi S., et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995, 26:111-123.
13. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
14. Brem S., Staller A., Wotoczek-Obadia M.E.A. Interstitial Chemotherapy for Local Control of CNS Metastases 2004.
15. Brem S., Tyler B., Li K., et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 2007, 60:643-650.
16. Brigger I., Morizet J., Aubert G., et al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther 2002, 303:928-936.
17. Brigger I., Morizet J., Laudani L., et al. Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. J Control Release 2004, 100:29-40.
18. Cahan M.A., Walter K.A., Colvin O.M., et al. Cytotoxicity of Taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 1994, 33:441-444.
19. Chasin M., Domb A., Ron E., et al. Polyanhydrides as drug delivery systems. Biodegradable Polymers as Drug Delivery Systems 1990, 43-70. Marcel Dekker, New York. M. Chasin, R. Langer (Eds.).
20. Chen M.Y., Lonser R.R., Morrison P.F., et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999, 90:315-320.
21. Cohen M.H., Johnson J.R., Pazdur R. Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 2005, 11:6767-6771.
22. Degen J.W., Walbridge S., Vortmeyer A.O., et al. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 2003, 99:893-898.
23. Doz F., Berens M.E., Dougherty D.V., et al. Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J Neurooncol 1991, 11:27-35.
24. Elliott P.J., Hayward N.J., Dean R.L., et al. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res 1996, 56:3998-4005.
25. Emerich D.F., Winn S.R., Bartus R.T. Injection of chemotherapeutic microspheres and glioma. III: Parameters to optimize efficacy. Cell Transplant 2002, 11:35-45.
26. Ettinger D.S. Evaluation of new drugs in untreated patients with small-cell lung cancer: its time has come. J Clin Oncol 1990, 8:374-377.
27. Ewend M.G., Williams J.A., Tabassi K., et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 1996, 56:5217-5223.
28. Ewend M.G., Sampath P., Williams J.A., et al. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 1998, 43:1185-1193.
29. Ewend M.G., Thompson R.C., Anderson R., et al. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J Immunother 2000, 23:438-448.
30. Ewend M.G., Brem S., Gilbert M., et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 2007, 13:3637-3641.
31. Fenteany G., Standaert R.F., Lane W.S., et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995, 268:726-731.
32. Fine H.A. Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin 1995, 13:827-846.
33. Fournier E., Passirani C., Montero-Menei C., et al. Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on f98 glioma-bearing rats. Cancer 2003, 97:2822-2829.
34. Fournier E., Passirani C., Vonarbourg A., et al. Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. Int J Pharm 2003, 268:31-35.
35. Frazza E.J., Schmitt E.E. A new absorbable suture. J Biomed Mater Res 1971, 5:43-58.
36. 6 -benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 2002, 1:943-948.
37. Fung L.K., Ewend M.G., Sills A., et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998, 58:672-684.
38. Gansbacher B., Zier K., Daniels B., et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990, 172:1217-1224.
39. Gaynon P.S., Ettinger L.J., Baum E.S., et al. Carboplatin in childhood brain tumors. A Children's Cancer Study Group phase II trial. Cancer 1990, 66:2465-2469.
40. Ghersi-Egea J.F., Leininger-Muller B., Cecchelli R., et al. Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol Lett 1995, 82-83:645-653.
41. Glantz M.J., Choy H., Kearns C.M., et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 1995, 87:1077-1081.
42. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
43. Golden G.A., Meldorf M. Patients with metastatic brain cancer, undergoing resection and Gliadel® implantation experienced low local recurrence rates in the PROLONG Registry 2004, PROLONG Study Group.
44. Greig N.H. Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987, 14:1-28.
45. Grossman S.A., Reinhard C., Colvin O.M., et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992, 76:640-647.
46. Hamilton J.F., Morrison P.F., Chen M.Y., et al. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp Neurol 2001, 168:155-161.
47. Hannigan E.V., Green S., Alberts D.S., et al. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 1993, 50:2-9.
48. Hirakawa W., Kadota K., Asakura T., et al. Local chemotherapy for malignant brain tumors using methotrexate-containing fibrin glue. Gan To Kagaku Ryoho 1995, 22:805-809.
49. Howard M.A., Gross A., Grady M.S., et al. Intracerebral drug delivery in rats with lesion-induced memory deficits. J Neurosurg 1989, 71:105-112.
50. Hsu W., Lesniak M.S., Tyler B., et al. Local delivery of interleukin-2 and Adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol 2005, 74:135-140.
51. Judy K.D., Olivi A., Buahin K.G., et al. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J Neurosurg 1995, 82:481-486.
52. 3 H-taxol in the rat. Proc Am Assoc Cancer Res 1992, 34:380. (abstract).
53. Kleinberg L.R., Weingart J., Burger P., et al. Clinical course and pathologic findings after Gliadel® and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 2004, 22:1-9.
54. Knighton D., Ausprunk D., Tapper D., et al. Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer 1977, 35:347-356.
55. Kong Q., Kleinschmidt-Demasters B.K., Lillehei K.O. Intralesionally implanted cisplatin cures primary brain tumor in rats. J Surg Oncol 1997, 64:268-273.
56. Kornblith P.L., Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988, 68:1-17.
57. Koukourakis M.I., Giatromanolaki A., Schiza S., et al. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int J Radiat Oncol Biol Phys 1999, 43:107-114.
58. Kusuhara H., Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 1). Drug Discov Today 2001, 6:150-156.
59. Kusuhara H., Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 2). Drug Discov Today 2001, 6:206-212.
60. Langer R.S. Medical Applications of Controlled Release 1984, CRC Press, Boca Raton.
61. Langer R., Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976, 263:797-800.
62. Langer R., Brem H., Falterman K., et al. Isolations of a cartilage factor that inhibits tumor neovascularization. Science 1976, 193:70-72.
63. Laske D.W., Morrison P.F., Lieberman D.M., et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 1997, 87:586-594.
64. Lawson H.C., Sampath P., Bohan E., et al. Interstitial chemotherapy for malignant gliomas: The Johns Hopkins experience. J Neurooncol 2007, 83:61-70.
65. Lee J.K., Choi B., Sobel R.A., et al. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg 1990, 73:429-435.
66. Legnani F.G., Pradilla G., Thai Q.A., et al. Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers. J Neurooncol 2006, 77:225-232.
67. Lemaire L., Roullin V.G., Franconi F., et al. Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study. NMR Biomed 2001, 14:360-366.
68. Lemoli R.M., Gasparetto C., Scheinberg D.A., et al. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood 1991, 77:1829-1836.
69. Leong K.W., Brott B.C., Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res 1985, 19:941-955.
70. Leong K.W., Kost J., Mathiowitz E., et al. Polyanhydrides for controlled release of bioactive agents. Biomaterials 1986, 7:364-371.
71. Lesniak M.S., Brem H. Targeted therapy for brain tumours. Nat Rev 2004, 3:499-508.
72. Lesniak M.S., Upadhyay U., Goodwin R., et al. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005, 25:3825-3831.
73. Lewis D. Controlled release of bioactive agents from lactide/glycolide polymers. Biodegradable Polymers as Drug Delivery Systems 1990, 1-41. Marcel Dekker, New York. M. Chasin, R. Langer (Eds.).
74. Lidar Z., Mardor Y., Jonas T., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004, 100:472-479.
75. Lillehei K.O., Kong Q., Withrow S.J., et al. Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat. Neurosurgery 1996, 39:1191-1197.
76. Limentani S., Asher A., Heafner A., et al. A phase I trial of surgery, Gliadel® wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol 2005, 72:241-244.
77. Mardor Y., Roth Y., Lidar Z., et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001, 61:4971-4973.
78. Menei P., Daniel V., Montero-Menei C., et al. Biodegradation and brain tissue reaction to poly(d, l-lactide-co-glycolide) microspheres. Biomaterials 1993, 14:470-478.
79. Menei P., Benoit J.P., Boisdron-Celle M., et al. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 1994, 34:1058-1064.
80. Menei P., Boisdron-Celle M., Croue A., et al. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 1996, 39:117-123.
81. Menei P., Venier M.C., Gamelin E., et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer 1999, 86:325-330.
82. Menei P., Capelle L., Guyotat J., et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 2005, 56:242-248.
83. Moses M.A., Wiederschain D., Wu I., et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 1999, 96:2645-2650.
84. Oda Y., Tokuriki Y., Tsuda E., et al. Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in Silastic. Acta Neurochir Suppl (Wien) 1979, 28:489-490.
85. Olivi A., Gilbert M., Duncan K.L., et al. Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother Pharmacol 1993, 31:449-454.
86. Olivi A., Ewend M.G., Utsuki T., et al. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother Pharmacol 1996, 39:90-96.
87. Olivi A., Grossman S.A., Tatter S., et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol 2003, 21:1845-1849.
88. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995, 13:399-415.
89. Pardridge W.M. Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev 1999, 36:299-321.
90. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
91. 6 -benzylguanine. Biochemistry 1993, 32:11998-12006.
92. Pradier O., Rave-Frank M., Lehmann J., et al. Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CASKI). Int J Cancer 2001, 91:840-845.
93. Pradilla G., Legnani F.G., Petrangolini G., et al. Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. Neurosurgery 2005, 57:1032-1040.
94. Pradilla G., Wang P.P., Gabikian P., et al. Local intracerebral administration of paclitaxel with the paclimer delivery system: toxicity study in a canine model. J Neurooncol 2006, 76:131-138.
95. Prokai L., Prokai-Tatrai K., Bodor N. Targeting drugs to the brain by redox chemical delivery systems. Med Res Rev 2000, 20:367-416.
96. Rama B., Mandel T., Jansen J., et al. The intraneoplastic chemotherapy in a rat brain tumour model utilizing methotrexate-polymethylmethacrylate-pellets. Acta Neurochir (Wien) 1987, 87:70-75.
97. Raza S.M., Pradilla G., Legnani F.G., et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther 2005, 5:477-494.
98. Recht L.D., Glantz M.J., Meitner P., et al. Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). J Neurooncol 1998, 36:201-208.
99. Reece D.E., Barnett M.J., Connors J.M., et al. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 1993, 11:139-146.
100. Renaudin J., Fewer D., Wilson C.B., et al. Dose dependency of decadron in patients with partially excised brain tumors. J Neurosurg 1973, 39:302-305.
101. Ren H., Boulikas T., Lundstrom K., et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki Forest virus vector carrying the human interleukin-12 gene - a phase I/II clinical protocol. J Neurooncol 2003, 64:147-154.
102. 6 -benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 2000, 60:6307-6310.
103. Rhines L.D., Sampath P., DiMeco F., et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery 2003, 52:872-879.
104. Ringkjob R. Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol Scand 1968, 44:318-322.
105. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210:474-484.
106. Saini M., Roser F., Hussein S., et al. Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors. J Neurooncol 2004, 68:225-232.
107. Sampath P., Hanes J., DiMeco F., et al. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 1999, 59:2107-2114.
108. Sampson J.H., Akabani G., Archer G.E., et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PR-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003, 65:27-35.
109. Sawaya R., Ligon B.L., Bindal A.K., et al. Surgical treatment of metastatic brain tumors. J Neurooncol 1996, 27:269-277.
110. Shieh L., Tamada J., Chen I., et al. Erosion of a new family of biodegradable polyanhydrides. J Biomed Mater Res 1994, 28:1465-1475.
111. Shikani A.H., Eisele D.W., Domb A.J. Polymer delivery of chemotherapy for squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1994, 120:1242-1247.
112. Sipos E.P., Tyler B., Piantadosi S., et al. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997, 39:383-389.
113. Slichenmyer W.J., Rowinsky E.K., Donehower R.C., et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993, 85:271-291.
114. Storm P.B., Moriarity J.L., Tyler B., et al. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J Neurooncol 2002, 56:209-217.
115. Storm P.B., Renard V.M., Moriarity J.L., et al. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. Cancer Chemother Pharmacol 2004, 54:361-367.
116. Tamargo R.J., Epstein J.I., Reinhard C.S., et al. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 1989, 23:253-266.
117. Tamargo R.J., Leong K.W., Brem H. Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J Neurooncol 1990, 9:131-138.
118. Tamargo R.J., Bok R.A., Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991, 51:672-675.
119. Tamargo R.J., Myseros J.S., Epstein J.I., et al. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 1993, 53:329-333.
120. Thompson R.C., Pardoll D.M., Jaffee E.M., et al. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother Emphasis Tumor Immunol 1996, 19:405-413.
121. Vajkoczy P., Menger M.D. Vascular microenvironment in gliomas. J Neurooncol 2000, 50:99-108.
122. Valtonen S., Timonen U., Toivanen P., et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997, 41:44-48.
123. Voges J., Reszka R., Gossmann A., et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003, 54:479-487.
124. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
125. Warnke P.C., Blasberg R.G., Groothuis D.R. The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann Neurol 1987, 22:300-305.
126. Weber F., Asher A., Bucholz R., et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003, 64:125-137.
127. Weingart J.D., Sipos E.P., Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 1995, 82:635-640.
128. 6 -benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2007, 25:399-404.
129. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel® wafers) in patients with primary malignant glioma. Neuro-oncol 2003, 5:79-88.
130. Westphal M., Ram Z., Riddle V., et al. Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006, 148:269-275.
131. Yemisci M., Bozdag S., Cetin M., et al. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. Neurosurgery 2006, 59:1296-1302.